Mobile App

Google Play Apple Store
Quarterly Brief (July - September 2023): A Current Expert Analysis on Important HIV Clinical Decisions
AMA/ANCC/ACPE Activities
New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of new agents, changing regimen strategies and development of long-acting novel agents. This expanding era of simplified and effective HIV therapy presents physicians with many new opportunities and challenges for providing care. To deliver state-of-the-art HIV prevention and care, healthcare providers must stay informed regularly of new clinical data and treatment recommendations in HIV.

This educational Quarterly Brief, covering HIV data from July through September of 2023, will discuss the most clinically relevant information on HIV Prevention, ART Studies: Treatment-Naive, ART Studies: Treatment-Experienced and 4. Cardiometabolic Considerations and Other HIV Studies.
Review the Full Program or segment of interest. Claim up to 0.5 AMA, ANCC, or ACPE credit/contact hour(s) after completion of a brief post-test/evaluation.










Faculty Chair
Paul Sax, MD Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School

Faculty
Babafemi Taiwo, MD, MBBS Babafemi Taiwo, MD, MBBS
Chief, Division of Infectious Diseases
Gene Stollerman Professor of Medicine
Northwestern University
Feinberg School of Medicine

20
Supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Launch Date: October 30, 2023
Release Date: October 30, 2023
Expiration Date: September 30, 2024

09/30/2024
Mini Module
7628
QuarterlyBrief2023_WebBanner(1150).gif
False
HIV

CookieConsent

Change Settings